Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing drugs utilizing a novel method of action that enhances oxygen diffusion, today announced that it has been granted U.S. patent no. 7,351,844 entitled "Bipolar Trans Carotenoid Salts and Their Uses." This patent includes claims to a family of first-in-class new chemical entities, known as trans biopolar carotenoid (or TBC) molecules. In addition, the Company also announced it has been granted corresponding patents from the South African and the New Zealand Patent Offices.
Apr 8, 2008 - Optimer Pharmaceuticals, Inc. has received a 'Notice of Allowance' on a US patent application from the United States Patent and Trademark Office protecting its lead drug candidate, OPT-80, which is being developed for the treatment of Clostridium difficile infection, or CDI.
April 8, 2008 - Idera Pharmaceuticals, Inc. today announced the issuance of several patents. The claims of these patents cover novel immune modulatory oligonucleotides (IMO) and chemical modifications of IMOs, each of which provide unique immune responses.
Apr 8, 2008 -LinkMed's portfolio company AbSorber has been granted a patent in the U.S. for an AB0 column that the company is developing to facilitate transplantations between individuals of different blood groups. The patent concerns a molecule that is being developed to adsorb antibodies and is a substance patent.
No comments:
Post a Comment